Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients

Annamaria Colao, Carolina Di Somma, Stefano Spiezia, Mariagiovanna Filippella, Rosario Pivonello, Gaetano Lombardi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The prostate is a target organ of the GH and IGF-I axis because prostate hypertrophy is found in acromegaly, reduced prostate size is found in GH deficiency (GHD) patients, and additionally, IGF-I is reported to be a positive predictor factor of prostate cancer. To investigate whether GH replacement therapy in adult patients with GHD has adverse effects on the prostate, we studied the effect of 12-month GH or GH plus testosterone replacement on prostate pathophysiology in 24 adult patients with GHD (11 euandrogenemic and 13 hypoandrogenemic), compared with 24 age-matched healthy controls. At study entry, GHD patients had lower prostate volume than controls (19.4 ± 1.7 vs. 24.9 ± 1.7 ml; P = 0.03). After 12 months of treatment, all hypoandrogenemic patients achieved normal testosterone levels, and prostate volume increased in the patients to the same level as controls (25.0 ± 1.9 ml). The percentage increase in prostate volume was greater in hypoandrogenemic patients receiving both GH and testosterone replacement (51 ± 11%) than in those receiving GH replacement alone (15 ± 3%; P <0.0009). At baseline, prostate volume was similar in GHD patients below or above 60 yr of age (16.8 ± 1.3 vs. 23 ± 3.6 ml; P = 0.08), whereas after treatment it was higher in the latter patients (21.8 ± 1.2 vs. 29.5 ± 3.9 ml; P = 0.04). Prostate-specific antigen (PSA) and free PSA did not change, whereas PSA density was significantly reduced after treatment in hypoandrogenemic patients; there was also no change in calcifications, cysts, or nodules. In conclusion, GH replacement restores prostate size to normal in both young and elderly patients, with no increase in prostate abnormalities. Because the simultaneous treatment with GH and testosterone induces an increase of prostate size by 50% of baseline on average, care is suggested in elderly patients with prostate hyperplasia to avoid any risk of prostate symptoms. In these cases, GH replacement might be performed sequentially to reduce the hypertrophic effect of combining GH and testosterone.

Original languageEnglish
Pages (from-to)88-94
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume88
Issue number1
DOIs
Publication statusPublished - Jan 1 2003

Fingerprint

Growth Hormone
Testosterone
Prostate
Prostate-Specific Antigen
Insulin-Like Growth Factor I
Acromegaly
Hormone Replacement Therapy
Therapeutics
Hypertrophy
Hyperplasia
Cysts
Prostatic Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients. / Colao, Annamaria; Di Somma, Carolina; Spiezia, Stefano; Filippella, Mariagiovanna; Pivonello, Rosario; Lombardi, Gaetano.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 88, No. 1, 01.01.2003, p. 88-94.

Research output: Contribution to journalArticle

Colao, Annamaria ; Di Somma, Carolina ; Spiezia, Stefano ; Filippella, Mariagiovanna ; Pivonello, Rosario ; Lombardi, Gaetano. / Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients. In: Journal of Clinical Endocrinology and Metabolism. 2003 ; Vol. 88, No. 1. pp. 88-94.
@article{cc69f403c30d48e4b1068f4372c564ce,
title = "Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients",
abstract = "The prostate is a target organ of the GH and IGF-I axis because prostate hypertrophy is found in acromegaly, reduced prostate size is found in GH deficiency (GHD) patients, and additionally, IGF-I is reported to be a positive predictor factor of prostate cancer. To investigate whether GH replacement therapy in adult patients with GHD has adverse effects on the prostate, we studied the effect of 12-month GH or GH plus testosterone replacement on prostate pathophysiology in 24 adult patients with GHD (11 euandrogenemic and 13 hypoandrogenemic), compared with 24 age-matched healthy controls. At study entry, GHD patients had lower prostate volume than controls (19.4 ± 1.7 vs. 24.9 ± 1.7 ml; P = 0.03). After 12 months of treatment, all hypoandrogenemic patients achieved normal testosterone levels, and prostate volume increased in the patients to the same level as controls (25.0 ± 1.9 ml). The percentage increase in prostate volume was greater in hypoandrogenemic patients receiving both GH and testosterone replacement (51 ± 11{\%}) than in those receiving GH replacement alone (15 ± 3{\%}; P <0.0009). At baseline, prostate volume was similar in GHD patients below or above 60 yr of age (16.8 ± 1.3 vs. 23 ± 3.6 ml; P = 0.08), whereas after treatment it was higher in the latter patients (21.8 ± 1.2 vs. 29.5 ± 3.9 ml; P = 0.04). Prostate-specific antigen (PSA) and free PSA did not change, whereas PSA density was significantly reduced after treatment in hypoandrogenemic patients; there was also no change in calcifications, cysts, or nodules. In conclusion, GH replacement restores prostate size to normal in both young and elderly patients, with no increase in prostate abnormalities. Because the simultaneous treatment with GH and testosterone induces an increase of prostate size by 50{\%} of baseline on average, care is suggested in elderly patients with prostate hyperplasia to avoid any risk of prostate symptoms. In these cases, GH replacement might be performed sequentially to reduce the hypertrophic effect of combining GH and testosterone.",
author = "Annamaria Colao and {Di Somma}, Carolina and Stefano Spiezia and Mariagiovanna Filippella and Rosario Pivonello and Gaetano Lombardi",
year = "2003",
month = "1",
day = "1",
doi = "10.1210/jc.2002-020812",
language = "English",
volume = "88",
pages = "88--94",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Effect of growth hormone (GH) and/or testosterone replacement on the prostate in GH-deficient adult patients

AU - Colao, Annamaria

AU - Di Somma, Carolina

AU - Spiezia, Stefano

AU - Filippella, Mariagiovanna

AU - Pivonello, Rosario

AU - Lombardi, Gaetano

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The prostate is a target organ of the GH and IGF-I axis because prostate hypertrophy is found in acromegaly, reduced prostate size is found in GH deficiency (GHD) patients, and additionally, IGF-I is reported to be a positive predictor factor of prostate cancer. To investigate whether GH replacement therapy in adult patients with GHD has adverse effects on the prostate, we studied the effect of 12-month GH or GH plus testosterone replacement on prostate pathophysiology in 24 adult patients with GHD (11 euandrogenemic and 13 hypoandrogenemic), compared with 24 age-matched healthy controls. At study entry, GHD patients had lower prostate volume than controls (19.4 ± 1.7 vs. 24.9 ± 1.7 ml; P = 0.03). After 12 months of treatment, all hypoandrogenemic patients achieved normal testosterone levels, and prostate volume increased in the patients to the same level as controls (25.0 ± 1.9 ml). The percentage increase in prostate volume was greater in hypoandrogenemic patients receiving both GH and testosterone replacement (51 ± 11%) than in those receiving GH replacement alone (15 ± 3%; P <0.0009). At baseline, prostate volume was similar in GHD patients below or above 60 yr of age (16.8 ± 1.3 vs. 23 ± 3.6 ml; P = 0.08), whereas after treatment it was higher in the latter patients (21.8 ± 1.2 vs. 29.5 ± 3.9 ml; P = 0.04). Prostate-specific antigen (PSA) and free PSA did not change, whereas PSA density was significantly reduced after treatment in hypoandrogenemic patients; there was also no change in calcifications, cysts, or nodules. In conclusion, GH replacement restores prostate size to normal in both young and elderly patients, with no increase in prostate abnormalities. Because the simultaneous treatment with GH and testosterone induces an increase of prostate size by 50% of baseline on average, care is suggested in elderly patients with prostate hyperplasia to avoid any risk of prostate symptoms. In these cases, GH replacement might be performed sequentially to reduce the hypertrophic effect of combining GH and testosterone.

AB - The prostate is a target organ of the GH and IGF-I axis because prostate hypertrophy is found in acromegaly, reduced prostate size is found in GH deficiency (GHD) patients, and additionally, IGF-I is reported to be a positive predictor factor of prostate cancer. To investigate whether GH replacement therapy in adult patients with GHD has adverse effects on the prostate, we studied the effect of 12-month GH or GH plus testosterone replacement on prostate pathophysiology in 24 adult patients with GHD (11 euandrogenemic and 13 hypoandrogenemic), compared with 24 age-matched healthy controls. At study entry, GHD patients had lower prostate volume than controls (19.4 ± 1.7 vs. 24.9 ± 1.7 ml; P = 0.03). After 12 months of treatment, all hypoandrogenemic patients achieved normal testosterone levels, and prostate volume increased in the patients to the same level as controls (25.0 ± 1.9 ml). The percentage increase in prostate volume was greater in hypoandrogenemic patients receiving both GH and testosterone replacement (51 ± 11%) than in those receiving GH replacement alone (15 ± 3%; P <0.0009). At baseline, prostate volume was similar in GHD patients below or above 60 yr of age (16.8 ± 1.3 vs. 23 ± 3.6 ml; P = 0.08), whereas after treatment it was higher in the latter patients (21.8 ± 1.2 vs. 29.5 ± 3.9 ml; P = 0.04). Prostate-specific antigen (PSA) and free PSA did not change, whereas PSA density was significantly reduced after treatment in hypoandrogenemic patients; there was also no change in calcifications, cysts, or nodules. In conclusion, GH replacement restores prostate size to normal in both young and elderly patients, with no increase in prostate abnormalities. Because the simultaneous treatment with GH and testosterone induces an increase of prostate size by 50% of baseline on average, care is suggested in elderly patients with prostate hyperplasia to avoid any risk of prostate symptoms. In these cases, GH replacement might be performed sequentially to reduce the hypertrophic effect of combining GH and testosterone.

UR - http://www.scopus.com/inward/record.url?scp=0037238612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037238612&partnerID=8YFLogxK

U2 - 10.1210/jc.2002-020812

DO - 10.1210/jc.2002-020812

M3 - Article

VL - 88

SP - 88

EP - 94

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -